Germany - Pharmaceuticals

Description

The subject of this publication is the conclusion of agreements according to § 130 a para. 8 SGB V on finished medicinal products with different active substances or combinations of active substances within the framework of a so-called "open-house model".accession or conclusion of an agreement can take place at any time and under the same conditions. Individual contract negotiations are not carried out.the earliest contract start is 1.7.2020. Based on this, the contract term is a maximum of 24 months. The contract ends on 30.6.2022, in each case independent of the start of the contract.Should the AOK Hessen carry out a call for tenders for exclusive contracts in the form of an open procedure during the contract period for the active ingredients, the contracts concluded within the framework of this publication will be terminated in accordance with the contractual regulations.
Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be offered the opportunity to conclude or join a discount agreement in accordance with § 130 a para. 8 SGB V for the active substances listed in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents completely filled out and signed. A contract is concluded with each pharmaceutical company that fulfils the participation requirements. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, publication is made in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice is used. The resulting conceptual requirements, such as the procedural designation "open procedure", are solely due to the use of this contract notice form and the publication platform. This does not imply any further significance, in particular submission to regulations under public procurement law, unless they are mandatory for legal reasons. Subject to the provision of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount agreement pursuant to Section 130 a (8) of the German Social Code, Book V (SGB V) for the active substances listed in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents completely filled out and signed. A contract is concluded with each pharmaceutical company that fulfils the participation requirements. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, publication is made in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice is used. The resulting conceptual requirements, such as the procedural designation "open procedure", are solely due to the use of this contract notice form and the publication platform. This does not imply any further significance, in particular submission to regulations under public procurement law, unless they are legally binding. Subject to the provision of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount agreement pursuant to Section 130 a (8) of the German Social Code, Book V (SGB V) for the active substances listed in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents completely filled out and signed. A contract is concluded with each pharmaceutical company that fulfils the participation requirements. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, publication is made in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice shall be used. The resulting conceptual specifications, such as the procedural designation "open procedure", are solely due to the use of this contract notice form and the publication platform. This does not imply any further significance, in particular submission to regulations under public procurement law, unless they are legally binding. Subject to the provision of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount agreement pursuant to Section 130 a (8) of the German Social Code, Book V (SGB V) for the active substances listed in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents completely filled out and signed. A contract is concluded with each pharmaceutical company that fulfils the participation requirements. Exclusivity is not given. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, publication is made in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice is used. The resulting conceptual requirements, such as the procedural designation "open procedure", are solely due to the use of this contract notice form and the publication platform. This does not imply any further significance, in particular submission to regulations under public procurement law, unless they are mandatory for legal reasons. Subject to the provision of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount agreement pursuant to Section 130 a (8) of the German Social Code, Book V (SGB V) for the active substances listed in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents completely filled out and signed. A contract is concluded with each pharmaceutical company that fulfils the participation requirements. This publication does not constitute the award of a public contract within the meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, publication is in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice is used. The resulting conceptual specifications, such as the procedure designation "open procedure", are solely due to the use of this contract notice form and the publication platform. This does not imply any further significance, in particular submission to regulations under public procurement law, unless they are mandatory for legal reasons.

Opportunity closing date

01 May 2022

Value of contract

to be confirmed